Oritavancin diphosphate is a second-generation, semi-synthetic lipoglycopeptide, that is derived from chloroeremomycin, an analogue of vancomycin. Similar to vancomycin, it contains a core heptapeptide, however, its unique lipophilic side chain provides oritavancin with a prolonged half-life compared to the parent drug. Oritavancin has a multifaceted mechanism of action that displays concentration-dependent effects against gram-positive organisms. Similar to vancomcyin and other glycopeptides, oritavancin inhibits cell wall biosynthesis by binding noncovalently to the D-alanyl-D-alanine terminal ends of the peptidoglycan chain and pentaglycine bridge, thereby inhibiting transglycosylation and transpeptidation.
≥98% by HPLC